Significant benefit seen for neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab
Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy
Increased radiation with SABR boost seems to enhance local control but with reduced overall survival at highest dose
Greater incidence of grade 3 or higher adverse events from any cause seen in combination group versus monotherapy
Improvement in overall survival seen for patients receiving cisplatin or carboplatin with pemetrexed
First-line atezolizumab monotherapy is associated with improved overall survival compared with single-agent chemotherapy
Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer
Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites
<p style="margin-left: 20px;">Progression-free survival significantly longer with tislelizumab plus chemotherapy versus chemotherapy alone
Cosela reduces the frequency of bone marrow suppression caused by chemotherapy for extensive-stage small cell lung cancer